Denali Therapeutics Inc. (DNLI) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in South San Francisco, CA, United States. Der aktuelle CEO ist Ryan J. Watts.
DNLI hat IPO-Datum 2017-12-08, 443 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Select, eine Marktkapitalisierung von $3.2B.
Denali Therapeutics Inc. is a biopharmaceutical company headquartered in South San Francisco, California, focused on discovering and developing therapeutic candidates for neurodegenerative diseases. The company's pipeline includes several clinical-stage programs, such as BIIB122/DNL151, a LRRK2 inhibitor in Phase I/Ib trials for Parkinson's disease, DNL310 for Hunter syndrome, DNL343 for ALS, and SAR443122/DNL758 for cutaneous lupus erythematosus. Denali has established strategic collaborations with leading pharmaceutical and research institutions including Takeda, Genentech, Sanofi, and Harvard University to advance its antisense therapy platform and other neurodegenerative disease treatments. The company was incorporated in 2013 and operates under its current name since March 2015.
